| Abstrakt: |
Data collected included demographics, medication chart and inpatient note drug allergy documentation, culprit drug prescribing, consistency of drug allergy documentation throughout admissions and Adverse Drug Reaction (ADR) alerts. When evaluated in terms of treatment results, 15 (60%) patients successfully completed the treatment; 1 (4%) patient was excluded from follow-up; 3 (12%) patients were transferred abroad, 6 (24%) patients are still under treatment. MicroRNA expression in patients with allergic rhinitis during grass pollen immunotherapy K. Specjalski*; A. Maciejewska; J. Romantowski; R. Pawlowski; E. Jassem; M. Niedoszytko Medical University of Gda'nsk, Gda'nsk, Poland B Background: b Subcutaneous immunotherapy (SCIT) is a well-established method of treatment of allergic rhinitis (AR) resulting in symptoms and pharmacotherapy reduction, and better quality of life. B Results: b 2677 patient treated for tuberculosis; 210 patients were consulted to the Allergy; 25 drug-resistant patients seen by the authors.12 (48%) of the cases were women; mean age 37.24 ± 14.44 years; type 1 hypersensitivity reaction in 13 (52%) cases; 16 (64%) of them are citizens of the Republic of Turkey; 24 (96%) of them were diagnosed bacteriologically; 21 (84%) had pulmonary tuberculosis; 5 (20%) of them had previously received antituberculosis treatment. Drug allergy was ruled out in 83% of the patients and confirmed in the remaining 17%, with positive skin tests in 1 patient (with immediate reaction) and requiring a controlled oral exposure test in the remaining cases. [Extracted from the article] |
Plný text